All Posts

beyfortus-for-respiratory-syncytial-virus-treatment
Beyfortus: A New Respiratory Syncytial Virus (RSV) Drug for Toddlers

Sanofi’s immunization strategy is taking shape, owing to an authorization that could drive the company and its partner AstraZeneca to the forefront of the respiratory syncytial virus (RSV) treatment battle. The FDA approved Sanofi and AstraZeneca’s monoclonal antibody Beyfortus, also known as nirsevimab, as a preve...

Find More

MedTech News for Relievant, EarliTec, ReddyPort
Relievant Medsystems Launched Ablation System; Thermo Fisher’s Reproductive Health Assays; EarliTec’s Next-Generation EarliPoint Evaluation for ASD; FDA Cleared ReddyPort® Non-Invasive Ventilation Device; EndoTheia’s Novel Medical Device for Endoscopic Surgery; Neurolief’s MOOD Trial Interim Analysis

Relievant Medsystems Launched New Tools for its Ablation System On June 14, 2023, Relievant Medsystems announced that it launched its next-generation access instruments for the Intracept procedure. Chronic vertebrogenic low back pain is treated with Intracept, a minimally invasive, same-day, outpatient proced...

Find More

FemTech Market Outlook
Unlocking the Future of Women’s Healthcare Market: The Promise of FemTech

The concept of FemTech has gained immense popularity in recent years. FemTech, an acronym for female technology, refers to the application of technology and innovation to address the health concerns of women and offer solutions that are suited to their particular requirements. It includes a wide range of diagnostic...

Find More

Pharma News for Eli Lilly, Alnylam, Elevar
Lilly to Acquire Versanis; FDA Approves Beyfortus for RSV in Infants; Alnylam Presented Updates on Interim Phase 1 Results for ALN-APP; FDA Accepts NDA for Rivoceranib Plus Camrelizumab; FDA Fast Track Designation to Karyopharm’s Selinexor; Adcentrx’s IND Application for ADRX-0706

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases Eli Lilly & Company and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical firm focused on the discovery of novel medications for the treatment of cardiometab...

Find More

Inflammatory Myositis Treatment Outlook
Analyzing Strategies in Polymyositis and Dermatomyositis Treatment 

Inflammatory myositis refers to a group of disorders affecting the muscles and may be associated with different causes such as infection, drug toxicity, trauma, and autoimmune diseases. The most prominent cause of myositis is an autoimmune disease, typically known as idiopathic inflammatory myopathy (IIM). The indi...

Find More

biomarins-roctavian-first-hemophilia-a-gene-therapy
The Future is Here: BioMarin’s Roctavian First Hemophilia A Gene Therapy Paving the Way for a Cure

Hemophilia A is a rare genetic bleeding disorder that primarily affects males. Hemophilia A is the most common type of hemophilia, accounting for approximately 80% of all cases. It is estimated to occur in about 1 in 5,000 to 10,000 male births. As per the Centers for Disease Control (CDC) (2020), the estimated pre...

Find More

MedTech News for ResMed, Stryker, OncoBeta
ResMed Acquired Somnoware; Stryker Launched Q Guidance System; AlloSource’s AceConnex Pre-Sutured Fascia; Urotronic’s Optilume BPH Catheter System; Verve Medical’s Pivotal Trial of RPD Renal Pelvic Denervation System; OncoBeta Provided Update on Rhenium-SCT

ResMed Acquired Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software On July 05, 2023, ResMed acquired privately held Somnoware, a US leader in sleep and respiratory care diagnostics software.  The Somnoware software streamlines the processes of physicians as well as sleep and p...

Find More

Cloud Computing in Healthcare Industry
Cloud Computing in the Healthcare Industry: Revolutionizing Patient Care

The healthcare industry is witnessing immense growth and transformation owing to the ongoing development and adoption of new and innovative technologies and trends. Electronic Health Records (EHR), telemedicine, telehealth, medical research, and analytics, are some of the key technologies playing a crucial role in ...

Find More

Pharma News Astellas, Eisai, Iovance, Biophytis
FDA Grants Priority Review for Zolbetuximab BLA; FDA Traditional Approval for LEQEMBI for Alzheimer’s Disease; Iovance Announces Regulatory and Clinical Updates for TIL Therapy in Advanced NSCLC; Biophytis Seeks FDA Approval to Launch Phase 3 Study of Potential Treatment of Sarcopenia; Orphan Drug Designation to Marker Therapeutics’s MT-401 for AML Treatment; Axsome Therapeutics Initiates Phase 3 Trial of Solriamfetol for ADHD

Astellas Announces FDA Grants Priority Review for Zolbetuximab Biologics License Application Astellas Pharma Inc. announced that the FDA has accepted and granted Priority Review for the company's Biologics Licence Application (BLA) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-target...

Find More

leqembi-for-alzheimers-disease-treatment
Leqembi: A New Hope for Alzheimer’s Disease Patients

Alzheimer’s disease is the most common type of dementia, accounting for more than 60% of all cases, and is characterized by a gradual decline in cognitive and functional abilities. It represents a global health crisis that is increasing with the increasing geriatric population. It represents a global health crisis ...

Find More